Immunic. has been granted a patent for a white crystalline polymorph A of the calcium salt of a specific compound, characterized by distinct X-ray diffraction patterns. This polymorph is designed to inhibit dihydroorotate dehydrogenase (DHODH) and is intended for use in treating various diseases. GlobalData’s report on Immunic gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Immunic Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Immunic, Wearable breast pumps was a key innovation area identified from patents. Immunic's grant share as of June 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

Crystalline polymorph a of calcium salt compound

Source: United States Patent and Trademark Office (USPTO). Credit: Immunic Inc

The granted patent US12037305B2 describes a novel crystalline polymorph A of a hydrate of the calcium salt of a specific compound, referred to as formula I. The claims detail the unique characteristics of this polymorph, including its distinct X-ray diffraction patterns, FT Raman and IR absorption spectra, and 1H-NMR spectral data. Additionally, the patent outlines a pharmaceutical formulation that incorporates this polymorph along with a pharmaceutically acceptable excipient, emphasizing that the polymorph A should have a tetrahydrofuran (THF) content of less than 720 ppm. The polymorph is proposed for use in treating various diseases, including graft versus host reactions, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.

The patent also provides a comprehensive process for manufacturing crystalline polymorph A. This process involves several steps, including the preparation of a suspension from calcium hydroxide and a free acid form of the compound, followed by a series of washing, isolating, and slurring steps using organic solvents and water. Specific conditions such as temperature ranges for heating and the use of various organic solvents are detailed to ensure the successful production of the polymorph. The claims further include optional steps for drying, milling, and recrystallization to enhance the quality of the final product. Overall, the patent presents a systematic approach to both the characterization and production of this crystalline polymorph, which may have significant implications for pharmaceutical applications.

To know more about GlobalData’s detailed insights on Immunic, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies